Alt Immunopathogenesis of Type 1 Diabetes Mellitus

1. Auflage 2009
ISBN: 978-0-08-092173-0
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 300 Seiten, Web PDF

Advances in Immunology, a long-established and highly respected publication, presents current developments as well as comprehensive reviews in immunology.
This thematic volume focuses on the immunopathogenesis of type 1 diabetes mellitus. Edited and authored by the foremost scientists in this field, it provides up-to-date information and directions for future research.

Autoren/Hrsg.

Alt, Frederick W.

Inhaltsverzeichnis

1;Front Cover;1
2;Advances in Immunology;4
3;Copyright Page;5
4;Contents;6
5;Contributors;10
6;Chapter 1: Autoimmune Diabetes Mellitus-Much Progress, but Many Challenges;14
6.1;1. Models of Type 1 DM;15
6.2;2. The Histocompatibility Molecules of the Autoimmune Diabetic;16
6.3;3. The Diabetic Antigens and the Diabetogenic T Cells;16
6.4;4. The Genetics of Type 1 Diabetes;19
6.5;5. Development of New Therapies in the NOD Model Which Show Promise in Studies in Patients;20
6.6;6. Effects of Administration of Glutamic Acid Decarboxylase 65 (GAD 65) to Patients with Recent-Onset T1D;21
6.7;7. The Prospect for Trials to Prevent T1DM in Susceptible Human Populations;22
6.8;References;23
7;Chapter 2: CD3 Antibodies as Unique Tools to Restore Self-Tolerance in Established Autoimmunity: Their Mode of Action and Clinical Application in Type 1 Diabetes;26
7.1;1. Introduction;27
7.2;2. CD3 Antibodies as Promising Tolerance-Promoting Tools: The Proof of Concept in T1D;29
7.3;3. The Clinical Results in T1D: More than 25 Years of Effort;31
7.4;4. Why is the Effect of CD3-Antibody Based Therapy Antigen Specific and Long Lasting?;34
7.5;5. Building on the Present Clinical Experience to Improve CD3 Antibody Therapy in T1D;39
7.6;6. Conclusions;43
7.7;References;43
8;Chapter 3: GAD65 Autoimmunity-Clinical Studies;52
8.1;1. Introduction;53
8.2;2. GAD65 Autoimmunity in T1D;61
8.3;3. Pathogenesis of GAD65 Autoimmunity;74
8.4;4. Preclinical GAD65 Studies;77
8.5;5. Phase I GAD65 Clinical Studies;77
8.6;6. Phase II GAD65 Clinical Studies;78
8.7;7. Ongoing and Future Clinical Studies;80
8.8;8. Concluding Remarks;81
8.9;Acknowledgments;81
8.10;References;81
9;Chapter 4: CD8+ T Cells in Type 1 Diabetes;92
9.1;1. Introduction;93
9.2;2. MHC Class I and T1D;94
9.3;3. Autoreactive CD8+ T Cells in T1D;96
9.4;4. Antigens for Diabetogenic CD8+ T Cells in Humans;99
9.5;5. The Relative Contribution of the beta-Cell-Specific CD8+ Response to T1D;108
9.6;6. Development and Activation of Diabetogenic CD8+ T Cells;109
9.7;7. Recruitment of Diabetogenic CD8+ T Cells to Islets;117
9.8;8. Mechanisms of beta-Cell Cytotoxicity in T1D;118
9.9;9. Induction of Immunologic Tolerance in Diabetogenic CD8+ T Cells;121
9.10;10. Concluding Remarks;124
9.11;Acknowledgments;125
9.12;References;125
10;Chapter 5: Dysrulation of T Cell Peripheral Tolerance in Type 1 Diabetes;138
10.1;1. Introduction;139
10.2;2. The Autoimmune Process of T1D;139
10.3;3. Dysregulation of Central T Cell Tolerance in T1D;141
10.4;4. Dysregulation of Peripheral T Cell Tolerance in T1D;143
10.5;5. Summary;153
10.6;Acknowledgments;154
10.7;References;154
11;Chapter 6: Gene-Gene Interactions in the NOD Mouse Model of Type 1 Diabetes;164
11.1;1. Type 1 Diabetes is a Multigenic Disease;165
11.2;2. Insights into a Multigenic Disease: The NOD Mouse;166
11.3;3. Defining the Function of Alleles Altering the Frequency of T1D;174
11.4;4. Functional Studies with NOD Congenic Mice: The Combination of Protective Alleles at Idd3 and Idd5 Prevent Diabet;175
11.5;5. Review of Idd3;176
11.6;6. Review of Idd5;178
11.7;7. Genetic Complexity of Idd5: Genetic Masking and the Discovery of Idd5.3 and Idd5.4;180
11.8;8. Combining Protective Alleles at Il2/Idd3 with those from the Idd5 Subregions;181
11.9;9. Conclusion;182
11.10;Acknowledgments;183
11.11;References;183
12;Subject Index;190
13;Contents of Recent Volumes;194
14;Color Plates;200